New insights into the pathobiology and treatment of chronic myelogenous leukemia

被引:21
作者
Cotta, Claudlu V. [1 ]
Bueso-Ramos, Carlos E. [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Div Pathol & Lab Med, Houston, TX 77030 USA
关键词
CML; BCR-ABL; pathology; therapy; imatinib; staging;
D O I
10.1016/j.anndiagpath.2006.12.002
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Chronic myelogenous leukemia (CML) is one of the most frequently diagnosed forms of leukemia. Recent advances in the understanding of the molecular mechanisms involved in the pathogenesis of this disorder led to new diagnostic and therapeutic approaches. From a disease that used to be diagnosed purely on morphologic grounds, CML is now an entity that cannot be diagnosed in the absence of relevant cytogenetic or molecular data. Identification of the characteristic t(9;22) cytogenetic abnormality or of the BCR-ABL molecular abnormality is mandatory, as current treatment approaches rely on the use of agents active against this specific molecular target. This article presents the evolution in the understanding of the pathogenic mechanisms involved in CML, as well as the methods and the criteria currently in use in its diagnosis and treatment. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:68 / 78
页数:11
相关论文
共 65 条
[1]   LEUKEMIA IN SHOE-WORKERS EXPOSED CHRONICALLY TO BENZENE [J].
AKSOY, M ;
ERDEM, S ;
DINCOL, G .
BLOOD, 1974, 44 (06) :837-841
[2]  
Anastasi J, 1996, LEUKEMIA, V10, P795
[3]   Pseudo-Gaucher histiocytes identified up to 1 year after transplantation for CML are BCR/ABL-positive [J].
Anastasi, J ;
Musvee, T ;
Roulston, D ;
Domer, PH ;
Larson, RA ;
Vardiman, JW .
LEUKEMIA, 1998, 12 (02) :233-237
[4]   Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet [J].
Baccarani, Michele ;
Saglio, Giuseppe ;
Goldman, John ;
Hochhaus, Andreas ;
Simonsson, Bengt ;
Appelbaum, Frederick ;
Apperley, Jane ;
Cervantes, Francisco ;
Cortes, Jorge ;
Deininger, Michael ;
Gratwohl, Alois ;
Guilhot, Frangois ;
Horowitz, Mary ;
Hughes, Timothy ;
Kantarjian, Hagop ;
Larson, Richard ;
Niederwieser, Dielger ;
Silver, Richard ;
Hehlmann, Rudiger .
BLOOD, 2006, 108 (06) :1809-1820
[5]  
BAIKIE AG, 1969, AUSTRALAS ANN MED, V18, P7
[6]  
Bennett JH., 1845, EDINBURGH MED SURG J, P413
[7]   PROPOSALS FOR THE CLASSIFICATION OF THE MYELODYSPLASTIC SYNDROMES [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1982, 51 (02) :189-199
[8]   Inhibition of BCR-ABL expression with antisense oligodeoxynucleotides restores β1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitors [J].
Bhatia, R ;
Verfaillie, CM .
BLOOD, 1998, 91 (09) :3414-3422
[9]   RADIATION-RELATED LEUKEMIA IN HIROSHIMA AND NAGASAKI 1946-1964 .I. DISTRIBUTION INCIDENCE AND APPEARANCE TIME [J].
BIZZOZERO, OJ ;
JOHNSON, KG ;
CIOCCO, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1966, 274 (20) :1095-+
[10]   High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance [J].
Branford, S ;
Rudzki, Z ;
Walsh, S ;
Grigg, A ;
Arthur, C ;
Taylor, K ;
Herrmann, R ;
Lynch, KP ;
Hughes, TP .
BLOOD, 2002, 99 (09) :3472-3475